Arcadia Biosciences, Inc. (RKDA)

What Is Arcadia Biosciences?

Arcadia Biosciences, Inc. (Nasdaq: RKDA) is a publicly traded company headquartered in Davis, California that has undergone a radical business transformation. The company began as an agricultural biotechnology firm focused on developing improved crop traits — fundamentally, it was a seed company with a biotech twist. Today, Arcadia operates primarily as a consumer packaged goods company selling Zola coconut water to retail consumers. This shift from business-to-business agriculture into direct-to-consumer beverages is one of the most dramatic pivots any public agricultural biotech company has undertaken.

The Origins: Crop Traits

Arcadia Biosciences was founded to develop and commercialize novel traits in major and specialty crops. The company’s core technology was the ability to identify or engineer specific genes that improved crop yield, nutritional content, disease resistance, or other agronomic traits. The flagship product was GoodWheat™, a proprietary variety of wheat containing naturally higher fiber and lower gluten than conventional wheat, without sacrificing taste or texture. GoodWheat promised to serve health-conscious consumers and food manufacturers seeking clean-label ingredients.

The company also developed oilseed traits and other specialty crop products. The traditional business model was to license these traits to seed companies, agricultural corporations, or ingredient suppliers who would then market them to farmers and food makers. Revenue would come from trait royalties on each acre planted with the improved variety.

This business model was sound in theory but proved difficult in execution. Agricultural biotechnology is regulated heavily in many jurisdictions, trait adoption is slow (farmers are conservative), and the market is dominated by large agribusiness corporations. Arcadia, as an independent biotech company, struggled to achieve scale.

The Consumer Pivot: Zola Coconut Water

Rather than persist in a low-margin, slow-moving agricultural market, Arcadia made a bold choice. The company acquired Zola, a coconut water brand, and began building direct consumer relationships through retail channels. Coconut water is a beverage category that exploded in popularity in the 2010s and early 2020s — consumers view it as a natural, electrolyte-rich alternative to sports drinks and sugary beverages. Zola positioned itself in the premium segment, with cold-pressed products and clean-label messaging.

The Zola acquisition proved far more successful commercially than Arcadia’s legacy crop-traits business. Revenue from Zola climbed steadily, and the brand achieved shelf space in major retailers. In the first nine months of 2025, Zola revenue grew 26% year-over-year, and the product maintained gross margins above 30% for eleven consecutive quarters — a remarkable consistency for a consumer packaged goods business.

Exit from Agriculture

In 2025, Arcadia made the strategic decision to completely exit its legacy agricultural biotechnology business. The company sold its wheat traits business, including GoodWheat, to Above Food Corp. The sale provided Arcadia with non-dilutive capital — cash infusion without issuing new shares and diluting existing shareholders. With that capital and a streamlined cost structure, Arcadia doubled down on Zola as its primary business.

This exit marked the end of Arcadia’s identity as an agricultural biotechnology company. The company went from being a biotech innovator in crops to being a beverage distributor selling coconut water to supermarkets and online retailers. The transformation was complete.

How Zola Makes Money

Zola generates revenue through direct retail sales — consumers buy the product at grocery stores, health food shops, and online. The company likely sells through distribution and wholesale channels as well, meaning that retailers purchase the product from Arcadia at a wholesale price, then markup and resell to consumers at a retail price. The company’s gross margins — the revenue left after the cost of goods sold — have remained strong, typically above 30%, which suggests that Zola has pricing power and manages its supply chain efficiently.

For Arcadia, operating Zola is fundamentally different from operating a crop-traits business. Instead of licensing technology to agricultural companies, Arcadia must manage manufacturing partnerships, logistics, retail placement, and consumer marketing. This requires different operational expertise, but the financial model is more direct: each bottle sold generates immediate revenue, whereas trait royalties are long-delayed and uncertain.

The Pending Business Combination

In 2025, Arcadia announced a pending business combination with Roosevelt Resources. Under the terms, Roosevelt partners were expected to own approximately 90% of the combined entity post-combination, fundamentally changing the investment profile and control structure. This transaction signals that Arcadia’s current shareholders would see their ownership substantially diluted, though the details of the combination — whether Arcadia shareholders receive cash, stock in the combined entity, or some combination — would determine whether the deal is fair value.

The rationale for such a transaction is unclear from the public disclosures reviewed. Possible explanations include that Roosevelt Resources has strategic or operational resources (supply chain, manufacturing, distribution) that would accelerate Zola’s growth, or that Roosevelt is acquiring Arcadia primarily for its Zola brand, intending to integrate it into a larger consumer goods operation. The combination also gives Arcadia additional capital and potentially access to Roosevelt’s operational network.

Questions for Investors

The critical question for investors is whether Zola can sustain its growth trajectory and profitability as a standalone consumer brand. Coconut water is a mature category with established competitors, including larger players like Vita Coco. Arcadia’s shift from technology company to consumer goods company requires mastery of entirely different skills: retail marketing, supply chain management, consumer preferences, and competitive pricing.

The pending business combination with Roosevelt Resources introduces uncertainty about the future ownership and strategic direction of the company. Until the transaction closes, shareholders face both the opportunity that the combination will accelerate growth and the risk that their ownership stake will be substantially diluted.

How to Research Arcadia Biosciences

Arcadia Biosciences files with the SEC under CIK 0001469443. The company’s quarterly filings track Zola sales, gross margins, operating expenses, and the status of the Roosevelt Resources combination. Investors should look for quarterly revenue trends, updates on the transaction timeline, and commentary on competitive positioning in the coconut water market.

Key metrics to monitor are Zola revenue growth, gross margin consistency, and the company’s operating losses (which persist even as Zola sales grow, because Arcadia has overhead costs for the combination). The announcement of the Roosevelt Resources combination should include details on ownership stakes post-close, which will clarify the value proposition for current shareholders.

As with any single security, Arcadia’s shares trade at market prices. The company has a proven product with strong brand momentum, but a business combination that dilutes current shareholders and a mature consumer market add material risks. Nothing here is a recommendation to buy or sell — only a map of the company’s transformation from agricultural biotech to consumer beverages, and the strategic and market uncertainties that accompany that pivot.